A glucocorticoid
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Dexamethasone Phosphate (sodium salt)

Item No. 20340

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(11β,16α)-9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-pregna-1,4-diene-3,20-dione, disodium salt
CAS Number
2392-39-4
Synonyms
  • Dexamethasone 21-phosphate
  • Dexamethasone Sodium Phosphate
Molecular Formula
C22H28FO8P • 2Na
Formula Weight
516.4
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 10 mg/mlWater: 30 mg/ml
λmax
239 nm
SMILES
O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@]4(O)C(COP([O-])([O-])=O)=O)=C1.[Na+].[Na+]
InChi Code
InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1
InChi Key
PLCQGRYPOISRTQ-FCJDYXGNSA-L
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 mg

    $36

    Add

    500 mg

    $86

    Add

    1 g

    $135

    Add

    5 g

    $420

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Dexamethasone phosphate is a glucocorticoid.1 It reduces LPS-induced production of RANTES, TGF-β1, and nitric oxide (NO) in BV-2 microglia when used at concentrations ranging from 1 to 4 µM. Dexamethasone phosphate reverses LPS-induced decreases in IL-10 levels in, and inhibits LPS-induced migration of, BV-2 microglia when used at a concentration of 4 µM. In vivo, dexamethasone phosphate decreases motor activity and reduces adrenal weight and plasma corticosterone levels in rats when administered in the drinking water at a concentration of 5 µg/ml.2 Dexamethasone phosphate (1.6 mg/kg per day) reduces joint swelling in a rat model of collagen-induced arthritis when administered for a minimum of seven days.3 It also reduces pruritis and the clinical lesion score in cats with hypersensitivity dermatitis.4 Formulations containing dexamethasone phosphate have been used in the treatment of various inflammatory diseases, arthritis, and endocrine disorders.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hui, B., Yao, X., Zhang, L., et al. Dexamethasone sodium phosphate attenuates lipopolysaccharide-induced neuroinflammation in microglia BV2 cells. Naunyn Schmiedebergs Arch. Pharmacol. 393(9), 1761-1768 (2020).

    2. Katz, R.J., and Carroll, B.J. Endocrine control of psychomotor activity in the rat: Effects of chronic dexamethasone upon general activity. Physiol. Behav. 20(1), 25-30 (1978).

    3. Rauchhaus, U., Schwaiger, F.W., and Panzner, S. Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: Long-term suppression of arthritis facilitates interval treatment. Arthritis Res. Ther. 11(6), R190 (2009).

    4. McClintock, D., Austel, M., Gogal, R.M., Jr., et al. Oral dexamethasone sodium phosphate solution significantly reduces pruritus and clinical lesions in feline hypersensitivity dermatitis: An open-label study. Vet. Dermatol. 32(5), 497-e137 (2021).